California State Teachers Retirement System Has $20.83 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)

California State Teachers Retirement System lowered its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 3.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 500,867 shares of the company's stock after selling 16,129 shares during the quarter. California State Teachers Retirement System owned approximately 0.13% of Moderna worth $20,826,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Norges Bank acquired a new position in shares of Moderna in the fourth quarter worth approximately $163,833,000. Voloridge Investment Management LLC raised its stake in shares of Moderna by 335.6% in the fourth quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company's stock worth $107,727,000 after purchasing an additional 1,996,003 shares during the last quarter. FMR LLC raised its position in Moderna by 7.4% in the 4th quarter. FMR LLC now owns 18,664,634 shares of the company's stock valued at $776,075,000 after buying an additional 1,282,469 shares during the last quarter. Pictet Asset Management Holding SA increased its stake in Moderna by 170.5% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company's stock valued at $73,447,000 after buying an additional 1,113,455 shares during the last quarter. Finally, Invesco Ltd. increased its position in shares of Moderna by 24.3% during the fourth quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock valued at $208,169,000 after acquiring an additional 979,858 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on MRNA. Citigroup initiated coverage on shares of Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 target price for the company. UBS Group cut their target price on shares of Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Barclays cut their price objective on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research note on Friday, May 2nd. JPMorgan Chase & Co. dropped their price objective on Moderna from $33.00 to $26.00 and set an "underweight" rating for the company in a research note on Thursday, May 22nd. Finally, Royal Bank of Canada dropped their price objective on Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $53.58.

Moderna Stock Performance

Shares of MRNA stock traded up $1.22 on Tuesday, hitting $28.27. The stock had a trading volume of 6,168,176 shares, compared to its average volume of 8,180,935. The stock's 50 day moving average is $26.32 and its 200-day moving average is $33.75. The firm has a market capitalization of $10.93 billion, a price-to-earnings ratio of -3.05 and a beta of 1.86. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $158.82.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. The company had revenue of $108.00 million for the quarter, compared to analysts' expectations of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The business's revenue for the quarter was down 35.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($3.07) earnings per share. Equities analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.